Esperion Therapeutics, Inc.

NasdaqGM:ESPR Stock Report

Market Cap: US$798.1m

Esperion Therapeutics Management

Management criteria checks 3/4

Esperion Therapeutics' CEO is Sheldon Koenig, appointed in May 2021, has a tenure of 4.75 years. total yearly compensation is $3.18M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 0.21% of the company’s shares, worth $1.66M. The average tenure of the management team and the board of directors is 3.3 years and 3.6 years respectively.

Key information

Sheldon Koenig

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage23.49%
CEO tenure4.8yrs
CEO ownership0.2%
Management average tenure3.3yrs
Board average tenure3.6yrs

Recent management updates

Recent updates

Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now

Sep 09
User avatar

US FDA Approvals And Global Expansion Will Shape Future Markets

International expansion and strategic partnerships are anticipated to significantly boost global sales and royalty revenues over time.

Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug

Feb 22

Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Dec 08

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 13

Esperion Therapeutics: Strategically Positioned To Grow

Aug 16

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23
Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

CEO Compensation Analysis

How has Sheldon Koenig's remuneration changed compared to Esperion Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$106m

Jun 30 2025n/an/a

-US$104m

Mar 31 2025n/an/a

-US$153m

Dec 31 2024US$3mUS$746k

-US$52m

Sep 30 2024n/an/a

-US$87m

Jun 30 2024n/an/a

-US$98m

Mar 31 2024n/an/a

-US$87m

Dec 31 2023US$3mUS$721k

-US$209m

Sep 30 2023n/an/a

-US$208m

Jun 30 2023n/an/a

-US$222m

Mar 31 2023n/an/a

-US$239m

Dec 31 2022US$4mUS$683k

-US$234m

Sep 30 2022n/an/a

-US$243m

Jun 30 2022n/an/a

-US$258m

Mar 31 2022n/an/a

-US$235m

Dec 31 2021US$8mUS$566k

-US$269m

Sep 30 2021n/an/a

-US$308m

Jun 30 2021n/an/a

-US$325m

Mar 31 2021n/an/a

-US$156m

Dec 31 2020US$508kUS$23k

-US$144m

Compensation vs Market: Sheldon's total compensation ($USD3.18M) is about average for companies of similar size in the US market ($USD3.39M).

Compensation vs Earnings: Sheldon's compensation has increased whilst the company is unprofitable.

CEO

Sheldon Koenig (59 yo)

4.8yrs
Tenure
US$3,175,240
Compensation

Mr. Sheldon L. Koenig, M.B.A. is Business Advisor Sarcomatrix Therapeutics, Corp. Mr. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and h...

Leadership Team

NamePositionTenureCompensationOwnership
Sheldon Koenig
President4.8yrsUS$3.18m0.21%
$ 1.7m
Benjamin Halladay
Chief Financial Officer3.3yrsUS$1.37m0.069%
$ 553.0k
Benjamin Looker
General Counsel & Corporate Secretary4.1yrsUS$1.13m0.059%
$ 469.8k
Glenn Brame
Chief Technical Operations Officer3.1yrsno datano data
Tiffany Aldrich
Associate Director of Corporate Communicationsno datano datano data
Betty Swartz
Chief Business Officerno datano datano data
LeAnne Bloedon
VP & Head of Developmentno datano datano data
John Harlow
Chief Commercial Officerless than a yearno data0.18%
$ 1.4m
Stephen Pinkosky
Vice President of Drug Discovery of Early Pre-Clinical Developmentno datano datano data
3.3yrs
Average Tenure
50yo
Average Age

Experienced Management: ESPR's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sheldon Koenig
President4.8yrsUS$3.18m0.21%
$ 1.7m
Robert Hoffman
Independent Directorless than a yearno data0.0022%
$ 17.8k
Jay Shepard
Independent Director7.8yrsUS$174.83k0.036%
$ 284.8k
Stephen Rocamboli
Independent Director3.8yrsUS$172.33k0.029%
$ 233.2k
J. Carroll
Independent Chairperson3.7yrsUS$194.83k0.041%
$ 328.7k
Peter Libby
Member of Scientific Advisory Board3.5yrsno datano data
Seth H. Fischer
Independent Director4.3yrsUS$177.33k0.026%
$ 205.8k
Tracy Woody
Independent Director6.8yrsUS$176.16k0.014%
$ 113.0k
Erin Bohula
Member of Scientific Advisory Board3.5yrsno datano data
Jeffrey Bender
Member of Scientific Advisory Board3.5yrsno datano data
Karin Bornfeldt
Member of Scientific Advisory Board3.5yrsno datano data
Dennis Bruemmer
Member of Scientific Advisory Board3.5yrsno datano data
3.6yrs
Average Tenure
63yo
Average Age

Experienced Board: ESPR's board of directors are considered experienced (3.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/02 15:55
End of Day Share Price 2026/01/30 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Esperion Therapeutics, Inc. is covered by 17 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Kristen KluskaCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC